Drug Database
RH

Rho(D) Immune Globulin

✓ Approved

CSL Limited · Polyclonal Antibodies · Polyclonal Antibodies

What is Rho(D) Immune Globulin?

Rho(D) Immune Globulin is a polyclonal antibodies developed by CSL Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyCSL Limited
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, CSL Limited

Therapeutic Indications

Rho(D) Immune Globulin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersRhesus haemolytic disease of newborn✓ Approved

Related Research Articles

PubMedIrish journal of medical science2026-05-24

Association between cognitive dysfunction and upper extremity performance in multiple sclerosis: a cross-sectional study : Irish journal of medical science.

Erkoç Aybike A, Ünlüer Nezehat Özgül NÖ

Multiple sclerosis (MS) is a demyelinating disease that affects cognitive function and upper extremity performance. To investigate cognitive impairment and upper extremity performance in individuals with MS and to compare these parameters with those of healthy controls. The study included 32 individuals with MS and 30 healthy controls. Participants were assessed using the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA), Nine-Hole Peg Test, Upper Extremity Y Balance Test, Jamar® Hand Dynamometer, Ruler-Drop Reaction Time Test, Upper Extremity Functional Index-20 (UEFI-20), Modified Push-up Test, and Touching Discs Test. Compared with the control group, individuals with MS demonstrated lower scores in spatial perception (Z = 3.162, p = 0.002, r = 0.40), motor praxis (Z = 2.085, p = 0.037, r = 0.26), visual-motor organization (Z = 4.827, p < 0.001, r = 0.61), thinking skills (Z = 4.300, p < 0.001, r = 0.55), attention parameters (Z = 4.550, p < 0.001, r = 0.53), and total LOTCA scores (Z = 4.796, p < 0.001, r = 0.61,). In individuals with MS, spatial perception was associated with upper extremity endurance (rho = 0.350, p = 0.049), dominant upper extremity coordination (rho = 0.469, p = 0.007), non-dominant upper extremity coordination (rho = 0.463, p = 0.008), and dominant upper extremity fine motor skills (rho = 0.361, p = 0.042). Visual-motor organization was associated with upper extremity endurance (rho = 0.598, p < 0.001), dominant upper extremity coordination (rho = 0.402, p = 0.023), dominant reaction time (rho = 0.385, p = 0.029), non-dominant reaction time (rho = 0.523, p = 0.002), and selected upper extremity balance parameters (p < 0.05). Attention was related to upper extremity endurance (rho = 0.355, p = 0.046), dominant grip strength (rho = 0.365, p = 0.040), and non-dominant grip strength (rho = 0.393, p = 0.027). Total LOTCA scores were associated with upper extremity endurance (rho = 0.036, p = 0.846). Cognitive and upper extremity impairments coexist in MS, emphasizing cognitive assessment in rehabilitation.

PMID 42176168
Read full article →
PubMedFood chemistry2026-05-24

Study on the regulation of water-fat distribution, physical properties and gluten molecular conformation of frozen dough by amphiphilic Tremella polysaccharide - corn germ globulin gel.

Wang Hanmiao H, Yu Jiawei J, Zhang Yanrong Y, Zhang Shanshan S

This study investigated the effects of amphiphilic Tremella polysaccharide-corn germ globulin (TP-CG) on frozen dough during frozen storage. The results demonstrated that TP-CG improved the water and oil holding capacities of the dough, promoting the uniform distribution of water and fat. Additionally, TP-CG enhanced the viscoelasticity and tensile properties of the dough, thereby preserving gluten strength. At the molecular level, TP-CG stabilized disulfide bonds, promoted the ordered arrangement of gluten proteins, maintained the integrity of the gluten network structure, and strengthened intermolecular cross-linking. TP-CG also intensified interactions with gluten proteins, enhancing the stability of the ternary composite system and effectively inhibiting gluten protein degradation. Furthermore, TP-CG improved the fermentation performance of frozen dough, resulting in fluffier bread after baking. This study offers a novel strategy for the high-value utilization of edible fungi and corn resources, and provides new insights for the development of the frozen food industry.

PMID 42176486
Read full article →
PubMedMethods in cell biology2026-05-24

In vitro expansion of stem-like memory T cells via D-mannose supplementation.

Qiu Yajing Y, Zhao Congcong C, Li Guideng G, Huang Bo B

The therapeutic success of adoptive T cell therapy (ACT) is closely tied to the in vivo persistence and differentiation state of transferred T cells. Clinical evidence consistently shows that less differentiated T cells, particularly memory T cells with stem-like properties, offer superior antitumor activity and long-lasting immune responses. However, these stem-like memory T cells are challenging to expand efficiently using conventional in vitro culture protocols. Existing strategies, such as brief CD3/CD28 antibodies co-stimulation combined with cytokines like IL-7, IL-15, and IL-21, have shown limited success but remain costly and operationally complex, hindering scalability for clinical use. There is a critical need for a rapid, efficient, cost-effective, and clinically viable method to induce and expand this T cell subset. Here, we present an optimized mannose-based culture approach that enables robust in vitro expansion of stem-like memory T cells, offering a practical solution to current limitations and paving the way for improved ACT applications.

PMID 42177043
Read full article →
PubMedBiomaterials2026-05-24

Regorafenib and R837 nanoparticle-stabilized Pickering emulsions overcome the angiogenesis-immune tolerance axis in transarterial chemoembolization.

Peng Yisheng Y, Liu Hui H, Yang Lijuan L, Wu Xiuyi X et al.

Transarterial chemoembolization (TACE) is hindered by the instability of embolic agents, as well as the tumor microenvironment post-embolization, which is characterized by angiogenesis and immune tolerance. Here, we identify a coupled angiogenesis-immune tolerance axis as a key mechanism underlying post-TACE therapeutic resistance. In this study, we developed a novel combination formulation of regorafenib and R837 designed to reprogram the tumor microenvironment following embolization. Using a supercritical carbon dioxide-assisted method, we successfully synthesized carrier-free pure drug nanoparticles of regorafenib and R837, achieving nanoparticles-stabilized lipiodol Pickering emulsions (PE-RR) preparation. This stable formulation not only significantly enhances the embolic stability and sustained drug release, but also effectively reverses post-embolization hypoxia, angiogenesis and immune tolerance through the therapeutic combination of regorafenib and R837. This study demonstrated that locoregional therapy with PE-RR significantly suppressed the hypoxia-angiogenesis signaling axis. These effects are mediated by the coordinated inhibition of angiogenesis (HIF-1α/VEGF axis) and activation of anti-tumor immunity, establishing a mechanistic linkage between vascular normalization and immune reprogramming. By strengthening antigen release and localized delivery of immune agonists, PE-RR facilitated anti-tumor immune activation and improved the therapeutic response to embolization, overcoming the adverse tumor microenvironment associated with conventional lipiodol embolization. Additionally, in bilateral tumor models, PE-RR could boost the therapeutic efficacy of PD-1 checkpoint blockade, increase the generation of anti-tumor immune memory and minimize the low responsiveness of immune checkpoint inhibitors in liver cancer. The stable Pickering embolic emulsion offers an innovative approach for the clinical translation of embolization therapy.

PMID 42176393
Read full article →
PubMedCurrent treatment options in oncology2026-05-24

Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors.

Liu Chenlu C, Chang Le L, Yan Ying Y, Ji Huimin H et al.

Immune checkpoint inhibitors have reshaped the therapeutic landscape of hepatocellular carcinoma by restoring T cell-mediated antitumor immunity. However, the clinical benefit of monotherapy remains limited, highlighting the need for improved patient stratification and more effective treatment strategies. HBV-related hepatocellular carcinoma (HBV-HCC) is a major etiological subtype characterized by a chronically immunosuppressive tumor microenvironment driven by persistent viral antigen exposure and immune exhaustion. We believe that patients with HBV-HCC may be more suitable for immunotherapy, especially treatment with immune checkpoint inhibitors. A deeper understanding of the expression patterns of inhibitory checkpoint and costimulatory molecules, along with the identification of predictive biomarkers and the development of effective combination immunotherapies is essential for improving clinical outcomes. From a safety perspective, hepatitis B virus reactivation is generally manageable when appropriate antiviral therapy is administered concurrently with immunotherapy. Consequently, patients with HBV-HCC should not be excluded from treatment with immune checkpoint inhibitors. We anticipate that combination strategies, including multi-target immune checkpoint blockade, combinations with other immunotherapeutic approaches, and microbiome-based therapy, will further enhance therapeutic efficacy in HBV-HCC. Combination immune checkpoint therapy may enhance antitumor responses and potentially contribute to better control of viral activity.

PMID 42176073
Read full article →
PubMedOncogene2026-05-24

Lactic acid induces dendritic cell pyroptosis through MCT-1 to promote tumor immune evasion.

Yang Shengrui S, Lin Liyuan L, Zheng Xiang X, Li Jie J et al.

Elevated metabolites in the tumor microenvironment (TME), particularly lactic acid, create an immunosuppressive milieu that promotes immune escape and tumor progression. Dendritic cells (DCs) are pivotal in initiating and regulating immune responses against tumors. However, the impact of lactic acid on DC death in the TME remains unclear. Our study reveals that lactic acid induces dose-dependent pyroptosis of bone marrow-derived DCs (BMDCs) through GSDMD cleavage. Mechanistically, this process involves monocarboxylate transporter 1(MCT1)-mediated signaling via the K+/NLRP3/GSDMD axis, facilitating immune evasion and cancer progression. Furthermore, inhibiting MCT1 attenuated lactic acid-induced DC pyroptosis both in vitro and in vivo. These findings offer mechanistic insights into how lactic acid-mediated DC pyroptosis contributes to tumor immune evasion, suggesting potential targets for enhancing cancer therapies.

PMID 42177282
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Rho(D) Immune Globulin